Crinetics Pharmaceuticals, Inc. CRNX
Crinetics Pharmaceuticals, Inc. statistics & valuation
Market cap$3.9B
P / B3.9×
Net margin-6046.2%
Return on equity-46.9%
FCF margin-4985.5%
Return on capital-49.6%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | -446.3% |
| Net margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.3% | -103960.6% | -4226.5% | -1116.8% | -447.8% |
| FCF margin | -4985.5% | -22525.3% | -4318.1% | -2467.0% | -8258.3% | -87623.9% | -3929.0% | -845.1% | -478.4% |
| Return on assets | -41.3% | -20.8% | -33.8% | -46.5% | -30.7% | -40.2% | -38.7% | -15.8% | -58.7% |
| Return on equity | -46.9% | -22.5% | -39.8% | -51.8% | -32.4% | -43.7% | -43.0% | -16.9% | 61.0% |
| Current ratio | 12.32 | 23.04 | 13.07 | 12.45 | 21.55 | 16.92 | 14.79 | 21.03 | 16.91 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.